Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether Endostar pumping into vein with Gemcitabine-Cisplatin are more effective than Endostar with Gemcitabine-Cisplatin regularly in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Non-small Cell Lung Cancer
DRUG: Endostar -Continued Pumping into+GP|DRUG: Endostar -injecting into +GP
Progression free survival (PFS), two years
Overall survival (OS), two years|Clinical benefit rate (CBR), two years|Number of Participants With Adverse Events(AE) as a Measure of Safety and Tolerability, two years
Endostar have anti-tumor activity by against vascular endothelial growth factor for initial treatment. This study was designed to evaluate the safety and efficacy of Endostar Continued vein-pumping Combining with Gemcitabine-Cisplatin (GP)chemotherapy in patients with NSCLC,and seeking for more effective injection.